AstraZeneca Inks R&D Deal With Ramaswamy's Roivant for Hush-Hush Indication Post author:Sam Post published:October 18, 2017 Post category:BioPharma Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra. Source: BioSpace You Might Also Like Sarepta to Seek FDA Approval for Second DMD Treatment March 11, 2018 Arbutus' LNP Licensee Alnylam Initiates Rolling Submission of NDA to U.S. FDA for Patisiran November 16, 2017 MindChild Medical Inc. Announces Publication Of "Evaluation Of The Fetal QT Interval Using Non-Invasive Fetal ECG Technology" With The MERIDIAN Fetal Monitoring System April 9, 2017
Arbutus' LNP Licensee Alnylam Initiates Rolling Submission of NDA to U.S. FDA for Patisiran November 16, 2017
MindChild Medical Inc. Announces Publication Of "Evaluation Of The Fetal QT Interval Using Non-Invasive Fetal ECG Technology" With The MERIDIAN Fetal Monitoring System April 9, 2017
